Experimental HIV vaccine trial aims to boost immunity in people on suppressive therapy

NCT ID NCT06680479

Terminated Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tests a new therapeutic HIV vaccine (CH505 TF chTrimer) in 30 adults living with HIV who are on suppressive antiretroviral therapy. The vaccine is designed to stimulate the immune system to produce new antibodies against HIV. The study is currently suspended and focuses on safety and whether the vaccine can trigger a meaningful immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CH505 TF chTrimer vaccine with 3M-052-AF and aluminum hydroxide adjuvant

What this could lead to

If successful, this could point toward a way to train the immune system to better control HIV, potentially reducing reliance on daily antiretroviral therapy.

What could go wrong

This is a very early phase 1 trial with only 30 participants, so safety and immune response are still unknown. The trial is currently suspended, and many early vaccines fail to show enough benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1

Contacts and locations

Show contact details

Locations

Case CRS

Cleveland, Ohio, 44106, United States
Chapel Hill CRS

Chapel Hill, North Carolina, 27599-7215, United States
Cincinnati CRS

Cincinnati, Ohio, 45267-0405, United States
Columbia Physicians & Surgeons (P&S) CRS

New York, New York, 10032, United States
Harbor University of California Los Angeles Center CRS

Torrance, California, 90502-2052, United States
Houston Advancing Research Team CRS

Houston, Texas, 77030, United States
Johns Hopkins University CRS

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital CRS (MGH CRS)

Boston, Massachusetts, 02114, United States
New Jersey Medical School Clinical Research Center CRS

Newark, New Jersey, 07103, United States
Northwestern University CRS

Chicago, Illinois, 60611, United States
Ohio State University CRS

Columbus, Ohio, 43210, United States
Penn Therapeutics CRS

Philadelphia, Pennsylvania, 19104, United States
The Ponce de Leon Center CRS

Atlanta, Georgia, 30308-2012, United States
UCSD Antiviral Research Center CRS

San Diego, California, 92103, United States
University of California, Los Angeles CARE Center CRS

Los Angeles, California, 90035, United States
University of California, San Francisco HIV/AIDS CRS

San Francisco, California, 94110, United States
University of Colorado Hospital CRS

Aurora, Colorado, 80045, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Adult HIV Therapeutic Strategies Network CRS

Rochester, New York, 14642, United States
University of Washington Positive Research CRS

Seattle, Washington, 98104, United States
Vanderbilt Therapeutics (VT) CRS

Nashville, Tennessee, 37204, United States
Washington University Therapeutics (WT) CRS

St Louis, Missouri, 63110-1010, United States
Weill Cornell Chelsea CRS

New York, New York, 10010, United States
Weill Cornell Uptown CRS

New York, New York, 10065, United States